

Date: 26-02-2026

To,
The General Manager,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai - 400001

To,
Manager – Listing,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Mumbai - 400051

Ref: Scrip Code at BSE: 533259 and NSE: SASTASUNDR

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Intimation by Sastasundar Healthbuddy Limited (“SHBL”), a material subsidiary of the Company, regarding Outcome of its Board Meeting for granting in-principle approval to its restructuring process.

Dear Sir/ Madam,

Pursuant to regulation 30(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, it is hereby informed that the board of directors of Sastasundar Healthbuddy Limited (“Board or SHBL”), a material subsidiary of the Company, at its meeting held today has accorded its in-principle approval to a restructuring process (which may include a merger and/or demerger) whereby it shall ultimately merge into its holding company, Health X Platform Limited (formerly Sastasundar Ventures Limited), under a court-sanctioned scheme of arrangement (“Restructuring”). The Board is exploring the Restructuring as an option to ensure independent group structures for each of its health care and financial services business with an intent that the underlying economic interest of the shareholders of SHBL post-merger with the Company shall remain intact, however subject to the final valuation.

Please note that the in-principle approval of the Board for the Restructuring is under further evaluation and finalisation in due course. Further, the Restructuring is contingent on the closing of the transaction of sale by Mitsubishi Corporation, an existing shareholder of SHBL, of its entire shareholding to Envision India Fund, a QIB, pursuant to the share purchase agreement dated 25.02.2026 (“SPA”). A disclosure regarding the execution of the SPA has already been made by the Company on 25.02.2026 to the Stock Exchanges.

SHBL shall appoint necessary independent valuer(s) to carry out the valuation exercise and submit the report to the Board, after which the final decision on the Restructuring shall be taken. The Restructuring shall be subject to final approvals from the Board, being obtained as per applicable law, and be implemented in the next financial year, post finalisation of the accounts of the FY 25-26.

The said in-principle approval accorded by the Board is under further evaluation and finalisation by the Board in due course.

The Company received the aforesaid information from SHBL on February 26, 2026 at 1:16 PM. This is for your information and record.

Yours faithfully,
For Health X Platform Limited
(formerly known as Sastasundar Ventures Limited)

Pratap Singh
Company Secretary & Compliance Officer
M. No. A24081

HEALTH X PLATFORM LIMITED

(formerly known as Sastasundar Ventures Limited)

CIN: L65993WB1989PLC047002

Azimganj House, 2nd Floor, 7, Abanindra Nath Thakur Sarani, (Formerly Camac Street), Kolkata- 700 017
Tel: +91 33 2282 9330 | Email: info@sastasundar.com | Website: www.sastasundarventures.com